AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15003298
Drug: Enoxaparin 20mg
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20mg subcutaneous injection once daily for 3 weeks
Trial: 9543364
Drug: Methylprednisone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisone (5 mg/kg per day in four oral doses over 7 days)
Trial: 3291099
Drug: Timegadine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timegadine 500 mg/day
Trial: 28485008
Drug: L-carnosine as
RxNorm normalized name: L-Carnosine
DrugBank: Carnosine (DB11695)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnosine as adjuvant to fluvoxamine
Trial: 25212871
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg for the first day, 75 mg/day thereafter) plus aspirin (100 mg/day)
Trial: 25212871
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (300 mg/day)
Trial: 24377217
Drug: Jin's three-needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jin's three-needle therapy
Trial: 24377217
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (acupuncture and rehabilitation)
Trial: 24377217
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Jin's three-needle, rehabilitation, combined therapy)
Trial: 11246353
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L of PEG‐ELS with 20 mg bisacodyl
Trial: 11246353
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L of PEG‐ELS preceded by 296 mL of magnesium citrate
Trial: 11246353
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L of PEG‐ELS
Trial: 9141518
Drug: MK-386 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-386 0.1 mg
Trial: 9141518
Drug: MK-386 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-386 0.5 mg
Trial: 9141518
Drug: MK-386 5
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-386 5 mg
Trial: 9141518
Drug: MK-386 20
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-386 20 mg
Trial: 9141518
Drug: MK-386 50
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-386 50 mg
Trial: 8153915
Drug: Aminophylline (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (administered continuously for 48 hours after surgery)
Trial: 8153915
Drug: Aminophylline (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (administered for 24 hours after cholecystectomy)
Trial: 8153915
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group, administered for 24 hours after cholecystectomy)
Trial: 25614600
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (2 μg·min(‐1)·kg(‐1)) at rest
Trial: 25614600
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion during handgrip (HG) exercise
Trial: 23940227
Drug: FLAG-Ida (fludarabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLAG-Ida (fludarabine, cytarabine, G-CSF, idarubicin)
Trial: 23940227
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (1.5 g/m2 or 3 g/m2)
Trial: 23940227
Drug: Cytarabine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine (1.5 g/m2)
Trial: 18340256
Drug: Minimal-contact, delayed-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal-contact, delayed-treatment control condition
Trial: 12665158
Drug: Dihydrocodeine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine (60 mg single dose)
Trial: 9151543
Drug: Various concurrent
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various concurrent recruitment methods
Trial: 9151543
Drug: Complex trial
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex trial designs (e.g., pre-randomization placebo run-in, split-mouth designs)
Trial: 8400972
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mifepristone + 1 mg gemeprost
Trial: 8400972
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg mifepristone + 1 mg gemeprost
Trial: 8400972
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg mifepristone + 1 mg gemeprost
Trial: 31654548
Drug: Human fibrinogen
RxNorm normalized name: Human fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human fibrinogen concentrate (HFC; 4 g)
Trial: 31654548
Drug: Cryoprecipitate (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoprecipitate (two pools of 5 units, approximately 4.0-4.6 g fibrinogen)
Trial: 26354542
Drug: Improving dietary
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Improving dietary quality (increased fruit by +1 serving; 150 g/d, vegetables by +2 servings; 150 g/d, and dairy by +1 serving; 200-250 g/d)
Trial: 20354496
Drug: Low-volume zero-balanced
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume zero-balanced ultrafiltration (35 mL/kg)
Trial: 18207289
Drug: LGT/DEN4 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGT/DEN4 vaccine (10^3 PFU)
Trial: 16607233
Drug: Epoetin alfa,
RxNorm normalized name: EPOETIN ALFA,RECOMBINANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin alfa, 40,000 IU, administered subcutaneously once weekly (n=48)
Trial: 12869080
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of oral baclofen
Trial: 8605131
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (3.6 mg subcutaneously)
Trial: 8605131
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (3.6 mg subcutaneously) for 8 weeks
Trial: 8605131
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment regimens (Goserelin and Danazol)
Trial: 6355421
Drug: Captopril (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (0.5, 1.0, and 2.0 mg/kg)
Trial: 6355421
Drug: Captopril (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (after 1 week of treatment)
Trial: 3987782
Drug: Prazosin once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin once daily
Trial: 3987782
Drug: Prazosin twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin twice daily
Trial: 30081390
Drug: TAU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU plus twice-weekly medication reminders by SMS (n=62)
Trial: 30081390
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; n=70)
Trial: 26565928
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) program, 7-week duration
Trial: 26401779
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (100 mg/day)
Trial: 23818206
Drug: Montelukast tablets
RxNorm normalized name: montelukast Chewable Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast tablets and theophylline
Trial: 12828502
Drug: SLI‐381 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLI‐381 10, 20 or 30mg once daily
Trial: 10866908
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion at 10 mL/h (Group 1)
Trial: 10866908
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion at 5 mL/h plus PCA boluses (2.5 mL/30 min) (Group 2)
Trial: 10866908
Drug: PCA boluses
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA boluses only (10 mL/60 min) (Group 3)
Trial: 9103270
Drug: Brussels sprouts
RxNorm normalized name: Brussels sprouts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brussels sprouts (300 g per day)
Trial: 9103270
Drug: Glucosinolate-free vegetables
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosinolate-free vegetables (300 g per day)
Trial: 3095082
Drug: Ritanserin 20
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin 20 mg
Trial: 3095082
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg and 20 mg)
Trial: 31515632
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract (600 mg day-1 CurraNZ™ containing 210 mg anthocyanins)
Trial: 16647134
Drug: Pegaptanib sodium
RxNorm normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegaptanib sodium (1 mg)
Trial: 16647134
Drug: Pegaptanib sodium
RxNorm normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegaptanib sodium (3 mg)
Trial: 12960445
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg hydroxy‐progesterone caproate and 10 mg oestradiol valerate on days 2, 6, 10 and 14 after embryo transfer (group 2, n = 411)
Trial: 16941701
Drug: PEG-interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-interferon alpha-2b (PEG-IFN) monotherapy
Trial: 10743815
Drug: Bilateral SI
RxNorm normalized name: SIS-101-ADO
DrugBank: SIS-101-ADO (DB18085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral SI joint injections of triamcinolone hexacetonide (40 mg/joint) under computer tomographic guidance
Trial: 10743815
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly mentioned, but implied as patients without treatment)
Trial: 8614505
Drug: d-cycloserine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-cycloserine (15 mg)
Trial: 1390591
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (40 mg/day) + n-3 polyunsaturated fatty acids (5.3 g eicosapentaenoic and docosahexaenoic acids)
Trial: 1390591
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (5.3 g)
Trial: 17595895
Drug: Ciprofloxacin test
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin test formulation (Novell Pharmaceutical Laboratories, Indonesia)
Trial: 17595895
Drug: Ciprofloxacin reference
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin reference formulation (Quimica Farmaceutica Bayer, Spain)
Trial: 12495602
Drug: Cefepime 1
RxNorm normalized name: cefepime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 1 to 2 g IV twice daily or three times a day for 3 to 21 days
Trial: 12495602
Drug: Broad-spectrum combination
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum combination therapy (IV ampicillin, cephalothin, or ceftriaxone +/- aminoglycoside) for 3 to 21 days
Trial: 12495602
Drug: Broad-spectrum combination
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum combination therapy
Trial: 9577999
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose gabapentin monotherapy (3,000‐4,800 mg/day)
Trial: 9327485
Drug: Monthly newsletter
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly newsletter
Trial: 2021990
Drug: Diphenhydramine 40
RxNorm normalized name: diphenhydramine Oral Capsule [40 Winks]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 40 mg iv pretreatment with cimetidine 200 mg iv
Trial: 2021990
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg iv without diphenhydramine pretreatment
Trial: 7214686
Drug: Oxatomide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (30 mg/capsule, 2-4 capsules daily)
Trial: 7214686
Drug: Chlorpheniramine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (5 mg/capsule, 2-4 capsules daily)
Trial: 30741797
Drug: Relugolix (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix (40 mg, oral, once daily)
Trial: 30741797
Drug: Leuprorelin (1.88
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin (1.88 mg or 3.75 mg, monthly injection)
Trial: 27749616
Drug: Landmark-guided steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landmark-guided steroid injection (40 mg of methylprednisolone)
Trial: 23653426
Drug: 5-mg donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg donepezil
Trial: 23653426
Drug: 7.5-mg donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5-mg donepezil
Trial: 21854068
Drug: Pea protein
RxNorm normalized name: Pea Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pea protein hydrolysate (PPH) administered orally at doses of 100 and 200 mg/kg body weight to SHR; 3-week randomized double-blind placebo-controlled trial in humans.
Trial: 21854068
Drug: Unhydrolyzed pea
RxNorm normalized name: Pea
DrugBank: Pea (DB10551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unhydrolyzed pea protein isolate (PPI) administered orally to SHR.
Trial: 15792017
Drug: VIBOVITmama supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIBOVITmama supplementation (15 mg of zinc, 2 mg of copper, 20 microg of selenium)
Trial: 3013265
Drug: Enalapril 20-40
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20-40 mg plus hydrochlorothiazide 25-100 mg
Trial: 3013265
Drug: Atenolol 50-100
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50-100 mg plus hydrochlorothiazide 25-100 mg
Trial: 6355186
Drug: Prednisone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (15 mg/d per subject for 7 days)
Trial: 24313916
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 100 mg plus MTX
Trial: 24313916
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 200 mg plus MTX
Trial: 24313916
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg plus MTX
Trial: 17584318
Drug: Cyclosporin administered
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin administered before meals (group B)
Trial: 17584318
Drug: Cyclosporin administered
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin administered after meals (group A)
Trial: 11238232
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of ETEC vaccine
Trial: 11238232
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose of ETEC vaccine
Trial: 11238232
Drug: Two full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two full vaccine doses
Trial: 11238232
Drug: One-third of
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-third of a full dose of CFA-ETEC bacteria
Trial: 9840528
Drug: Liver embolization
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver embolization with gel foam powder
Trial: 30536797
Drug: Posaconazole oral
RxNorm normalized name: posaconazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension formulations
Trial: 30536797
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product of posaconazole oral suspension
Trial: 26001337
Drug: Relamorelin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relamorelin (100 μg/d, given subcutaneously)
Trial: 18773845
Drug: Aminobisphosphonates as
RxNorm normalized name: (dichloromethylene)bisphosphonic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminobisphosphonates as preventive treatment at the time of diagnosis of bone metastatic prostate cancer
Trial: 18773845
Drug: Local treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatments (external beam radiotherapy, bone surgery) and systemic treatments (androgen deprivation, chemotherapy)
Trial: 12709725
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg subcutaneous etanercept twice weekly for 24 weeks
Trial: 12709725
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg subcutaneous etanercept twice weekly for 24 weeks
Trial: 10932442
Drug: Integrated mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated mental health and substance use treatment program
Trial: 8981131
Drug: dl-norgestrel (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-norgestrel (2 mg) with ethinyl oestradiol (200 micrograms)
Trial: 8981131
Drug: levonorgestrel (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levonorgestrel (1 mg) with ethinyl oestradiol (200 micrograms)
Trial: 3908726
Drug: S6472 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S6472 (750 mg b.i.d.)
Trial: 3908726
Drug: Cefaclor (CCL)
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor (CCL) (750 mg t.i.d.)
Trial: 27455316
Drug: Montmorency tart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montmorency tart cherry concentrate (MC) supplementation (30 mL twice per day for 8 days)
Trial: 21832285
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (irinotecan with either bolus or infused 5-fluorouracil)
Trial: 19200959
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg GnRHa (buserelin) supplemented with 1,500 IU hCG
Trial: 17587713
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of acetylcholine
Trial: 17587713
Drug: hs-CRP >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP > or = 2 mg/L
Trial: 2533802
Drug: Ethanol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.5 g/kg) plus diazepam (5 mg)
Trial: 2533802
Drug: Ethanol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.5 g/kg) plus meclophenoxate (100 mg)
Trial: 2533802
Drug: Ethanol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.5 g/kg) plus placebo
Trial: 31054159
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (400 iU daily) drops
Trial: 31424481
Drug: Clopidogrel-Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-Aspirin
Trial: 25948166
Drug: OSTAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSTAP block with 20 ml 0.25% bupivacaine
Trial: 25948166
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (paracetamol, tenoxicam, and tramadol as required)
Trial: 20519697
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg day(-1) orally for 4 weeks)
Trial: 20519697
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg day(-1) orally for 4 weeks)
Trial: 11590500
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 (1.2 million IU/m2 once daily) in conjunction with HAART
Trial: 9547441
Drug: Nebivolol 2.5
RxNorm normalized name: nebivolol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 2.5 mg
Trial: 8147960
Drug: Intensified insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified insulin treatment
Trial: 2897299
Drug: Bisoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (100 mg)
Trial: 26707134
Drug: 0.25 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 μg/day calcitriol (n=48)